Alderaan Biotechnology develops therapeutic modalities that target CD25-positive cancer cells and suppressive Treg cells using a proprietary antibody-drug conjugate (ADC) strategy. The company also focuses on creating first-in-class antibodies against CD160-TM, a receptor overexpressed in solid tumors and hematologic malignancies, to enhance cancer treatment efficacy.
Funding
$22.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers evade treatment by expressing CD25 on tumor cells and suppressive Treg cells, creating an immunosuppressive microenvironment. Existing therapies often lack specificity, leading to off-target effects and limited efficacy in targeting these cells.
Solution
Alderaan Biotechnology is developing targeted cancer therapies using antibody-drug conjugates (ADCs) that selectively target CD25-positive cells and CD160-TM, a receptor overexpressed in solid tumors and hematologic malignancies. Their approach involves a proprietary IL-2 sparing, CD25-specific antibody to target CD25+ cancer cells in hematologic malignancies. Additionally, they are creating first-in-class antibodies against CD160-TM to enhance cancer treatment efficacy by targeting a novel NK cell receptor. These therapeutic modalities aim to improve treatment outcomes by directly targeting tumor cells and modulating the immune response within the tumor microenvironment.
Target Audience
The primary target audience includes patients with solid tumors and hematologic malignancies, as well as oncologists and researchers seeking more effective and targeted cancer therapies.
Features
- Proprietary antibody-drug conjugate (ADC) technology for targeted delivery of cytotoxic payloads
- CD25-specific antibodies designed to selectively target CD25-positive cancer cells and Treg cells
- First-in-class antibodies against CD160-TM, a novel NK cell receptor overexpressed in solid tumors and hematologic malignancies
- IL-2 sparing CD25-specific antibody to minimize off-target effects